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Abstract
Vitamin K is known to play an essential role in the coagulation cascade; however, a growing
body of research has found that a subtype of this vitamin, vitamin K2 (menaquinone), may have a
beneficial effect in osteoporosis, cardiovascular disease, and cancer. The purpose of this article is
to provide a comprehensive review of recent literature regarding menaquinone and its role in
human health. This review discusses the physiology of menaquinone, its clinical benefits in
cardiovascular disease, osteoporosis, and cancer, and how it may interact with certain
medications. The authors conclude that menaquinone supplementation has been shown to
improve carboxylation of osteocalcin and matrix-Gla protein to their active forms, two proteins
that possess important roles in calcium distribution. In the setting of cardiovascular disease,
menaquinone intake has been shown to lower the risk of coronary calcification and coronary
heart disease, and a randomized controlled trial has demonstrated that it can reduce arterial
stiffness. In osteoporosis, menaquinone has been shown in numerous randomized controlled
trials to decrease the rate of bone loss at the lumbar spine and forearm and reduce the risk of
fracture. In cancer, menaquinone intake has been shown to reduce overall incidence and
mortality; clinical trials have suggested that it may have a role in reducing recurrence and death
from hepatocellular carcinoma. However, in all clinical settings, more large randomized
controlled trials are needed to definitively determine the clinical benefits of menaquinone
supplementation, as many studies have failed to show any significant benefit. Lastly, more
research is needed to determine how menaquinone supplementation interacts with medications
such as warfarin, bile-acid sequestrants, orlistat, mineral oil and CYP3A4 substrates.
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Introduction
Vitamin K is known to play an essential role in the coagulation cascade; however, a growing
body of research has found that it may also have an effect on osteoporosis, cardiovascular
disease, and cancer. Many may be unaware that there are actually different forms of vitamin K,
and that these forms possess distinct functions. The form primarily involved with the production
of clotting factors is K1 (phylloquinone). The effects of K2 (menaquinone) have recently become
the subject of discussion, as literature has suggested that menaquinone may play a role in the
treatment of cardiovascular disease, osteoporosis, and cancer.1-3 Menaquinone activates proteins
such as osteocalcin (OC) and matrix-Gla protein (MGP), which are important regulators of
calcium distribution. Through these interactions, menaquinone can assist in the inhibition of
vascular calcification and the deposition of calcium into bone.4 This review discusses the
physiology of menaquinone, its clinical benefits in cardiovascular disease, osteoporosis, and
cancer, and how it may interact with certain medications.
Methods
NCBI’s PubMed database was utilized to search for literature pertaining to the clinical benefits
of menaquinone supplementation. Combinations of the following search terms were used:

vitamin K2, K2, menaquinone, menatetrenone, MK-4, MK-7, osteoporosis, fracture, bone mineral
density, cardiovascular, calcification, coronary artery disease, cancer, hepatocellular carcinoma,
warfarin, anticoagulation, pregnane X receptor. Primary and secondary sources were screened
for relevance by title and the contents of the abstract. Potential sources were then downloaded
and their contents were scrutinized for relevance. Priority was given to level 1 and 2 randomized
controlled trials (RCT) and meta-analyses; however, observational studies were also included in
the discussion.
Menaquinone Supplementation
Vitamin K is a family of seven structurally similar compounds, but only phylloquinone and
menaquinone have established roles in human physiology. Phylloquinone serves as an essential
cofactor for liver enzymes that carboxylate glutamic acid residues on clotting factors II, VII, IX,
X, protein C, and protein S.5 Menaquinone also serves as a cofactor for carboxylase enzymes;
however, the targets of these enzymes differ from phylloquinone (Figure 1). One of these targets
is the bone matrix protein, OC, which is activated by the carboxylation of three glutamic acid
residues and plays a critical role in the binding and deposition of hydroxyapatite mineral in
bone.6 Another target is MGP found in vascular smooth muscle cells; when MGP is
carboxylated, it inhibits vascular calcification.7
For adults, the recommended dietary intake of phylloquinone is between 50 and 120 µg/day.8
This can easily be obtained through consumption of leafy green vegetables like kale, collards,
and spinach; thus, phylloquinone deficiency is rare.9 However, sources of phylloquinone do not
contain significant quantities of menaquinone. Dietary menaquinone is found primarily in whole
milk, other dairy products, egg yolk, chicken, pork, beef, and natto (a Japanese food made from
fermented soybeans).7 The menaquinone in dairy products and natto is synthesized by
fermenting bacteria such as Bacillus subtilis; in meats, K1 and K3 are converted to K2 by living
tissue.10
A number of menaquinone subtypes exist; they differ by the number of prenyl units contained on
the isoprenoid side chain.7 Bacteria produce menaquinone of varying side chain lengths, the most
notable being the MK-7 subtype.11 Very high levels of MK-7, as much as 939 µg/100 g are
found in natto.7, 12 MK-4 is another important subtype that is produced in animal tissue and can
be acquired by consuming meat and dairy products; however, the levels are much lower than
those of MK-7 in natto.7 In the United States, the amount of MK-4 found in meat ranges from
0.2-31.6 µg/100 g, highest being found in chicken; in dairy products it ranges from 0.2-10.2
µg/100 g and is highest in hard cheese.13 Both MK-7 and MK-4 are available for
supplementation; however, the half-life and bioavailability of MK-7 has been found to be
superior to that of MK-4.14, 15
Several studies have examined the effect of MK-7 supplementation on the carboxylation of OC
and MGP; this research has found a dose-dependent relationship between the quantity of MK-7
and the carboxylation of OC and MGP.15-20 The daily amount of MK-7 required to influence
carboxylation of OC and MGP has been found to vary from 45 µg to 360 µg.15-20 This effect is
believed to have clinical significance due to the role that these proteins play in bone and the
cardiovascular system. High levels of dephospho-uncarboxylated MGP (du-MGP) and

uncarboxylated OC (uOC) have been associated with arterial stiffness and an increased risk of
fractures.21-23
Clinical Impact on Cardiovascular Disease
The benefits of menaquinone to the cardiovascular system have been evaluated by several
studies (Table 1). Level 2 cross sectional studies from the Netherlands have found that increased
menaquinone intake is associated with decreased coronary calcification and mortality from
coronary heart disease.24-27 Beulens et al. administered a food frequency questionnaire to 564
Dutch postmenopausal women and found a decreased relative risk of coronary calcification (RR
= 0.80, 95% CI: 0.65-0.98) with increased menaquinone intake but not phylloquinone.24
Geleijnse et al. and Gast et al. also studied the results of a food questionnaire taken by 4807 and
16,057 postmenopausal Dutch women respectively; these studies found that high menaquinone
intake was associated with a lower relative risk for coronary heart disease mortality (RR = 0.43,
95% CI: 0.24-0.77) and a lower hazard ratio for having coronary heart disease (HR = 0.91, 95%
CI: 0.85-1.00).25, 26
A level 2 RCT studied the effect of menaquinone supplementation (MK-7, 180 µg/day) on
arterial stiffness in 244 healthy postmenopausal Dutch women over a three year period.28 The
investigators monitored carotid and aortic stiffness, du-MGP levels, inflammatory markers
(interleukin-6, C-reactive protein, tumor necrosis factor-α), and markers of endothelial
dysfunction (vascular cell adhesion molecule, E-selectin, advanced glycation endproducts).
Menaquinone supplementation was found to significantly decrease the amount of du-MGP by
approximately 50%; there was no significant effect on inflammatory or endothelial markers.28
Additionally, after three years, the menaquinone treatment group demonstrated a significant
overall decrease in Stiffness Index β, a measure of the elastic properties of the arterial wall.28
Treatment group patients were further divided into two groups based on whether they had a high
or low baseline Stiffness Index β (a high Stiffness Index β indicates poorer vascular
characteristics). When data was adjusted for confounding variables such as age, BMI, cholesterol
lowering medication, and anti-hypertensive medication, menaquinone supplementation was
found to significantly decrease the Stiffness Index β of patients with high baseline Stiffness
Index β but not those with low baseline Stiffness Index β. This suggests that menaquinone was
more beneficial to patients with poorer vascular status. Furthermore, variables such as vessel
distention, compliance, distensibility, Young’s modulus, and carotid pulse wave velocity
demonstrated significant improvement from menaquinone supplementation only in patients with
high baseline Stiffness Index β. There was a significant overall improvement in aortic pulse
wave velocity, a measure of regional arterial stiffness; however, this effect was not significantly
demonstrated in either the high or low Stiffness Index β groups independently.28
This study was limited by a small sample size.28 The original power analysis was performed to
measure bone strength, which was the primary outcome measurement of the clinical trial (this
work is published separately); this resulted in a power of only 65% for detecting a significant
change in aortic pulse wave velocity.28, 29 Additionally, it should be noted that this clinical trial
was funded by NattoPharma® (Høvik, Norway), a major producer of commercially available
MK-7 supplements, and is therefore subject to funding bias. Despite these limitations, the study

provides evidence that menaquinone supplementation can reduce arterial stiffness, and that this
effect seems to be more pronounced in patients with poorer baseline vascular characteristics.
More RCTs are needed to both confirm the effect of menaquinone on arterial stiffness, and
determine whether this effect significantly reduces the incidence and mortality of cardiovascular
disease.
Clinical Impact on Osteoporosis
A number of level 1 RCTs have been performed to study the effects of menaquinone on
osteoporosis (Table 2).16, 29-34 A trial performed by Knapen et al., involving the same 244
patients from their study of menaquinone and arterial stiffness, found that menaquinone
supplementation (MK-7, 180 µg/day) decreased the rate of bone loss at the lumbar spine and
femoral neck but not at the total hip.28, 29 Although both the treatment and control groups
experienced bone loss over the three year trial, the treatment group exhibited significantly less
bone loss in lumbar spine after one year of supplementation. However, the decrease in the rate of
bone loss in the femoral neck only became significant in the third year of daily supplementation.
Additionally, they found that menaquinone supplementation significantly reduced the level of
uOC and increased carboxylated OC (cOC).29
Another level 1 RCT by Emaus et al. involved 334 healthy postmenopausal women who were
supplemented with MK-7 (360 µg/day) for one year.16 The investigators measured bone mineral
density (BMD) at the total hip, femoral neck, lumbar spine, and total body; they also measured
serum levels of cOC and uOC. At 12 months, there was no significant difference in the rate of
bone loss between the treatment and control group at any site; however, the treatment group
displayed significantly higher serum levels of cOC and reduced levels of uOC.16
A level 2 meta-analysis by Huang et al. evaluated the clinical impact of menaquinone
supplementation on osteoporosis from 19 level 1 and 2 RCTs (6,759 patients).35 The combined
results of 4 trials involving 190 postmenopausal women with osteoporosis revealed a significant
decrease in the loss of vertebral BMD after 6 months of MK-4 supplementation (45 mg/day).
The results of two studies involving 144 postmenopausal women without osteoporosis
demonstrated no significant benefit to vertebral BMD after 6 months of daily MK-4 (45 mg/day).
When looking at forearm BMD, the combined results of three studies demonstrated a significant
benefit to postmenopausal women with osteoporosis; however, there was no significant benefit
in women without osteoporosis. There was also no significant benefit to hip BMD when
combining the results of 6 studies; however, these studies only included women without
osteoporosis.35
Huang et al. also observed a significant overall increase in cOC and decrease in uOC at 6 and 12
months with menaquinone supplementation in women with and without osteoporosis.35 There
was no significant difference in the rate of adverse reactions with menaquinone supplementation,
and the most commonly reported adverse reactions were nausea or abdominal pain. Additionally,
the investigators pooled the results of 6 trials that evaluated the risk of osteoporotic fractures;
they found a significant reduction in the incidence of fractures (RR = 0.50, 95% CI: 0.33-0.74)
with menaquinone supplementation.35

Many of the trials included in this meta-analysis were limited by small sample sizes (<50
treatment group patients) and suffered from selection and reporting bias. Additionally, 11 of the
19 trials exclusively involved Japanese patients, and 15 trials involved supplementation with
MK-4, which has been found to have an inferior half-life and bioavailability compared to MK7.14, 15, 35
Menaquinone supplementation does appear to improve the carboxylation of OC in both
postmenopausal women with and without osteoporosis; however the clinical benefit of this effect
has not been strongly observed in postmenopausal women without osteoporosis. The current
literature indicates that menaquinone supplementation can decrease the rate of bone loss in the
lumbar spine and forearm and reduce the risk of fracture in postmenopausal women with
osteoporosis. There is considerable heterogeneity in the literature with regards to the subtype
(MK-4 vs. MK-7) and amount of menaquinone being administered. More large double-blinded
RCTs are needed to definitively understand the clinical impact of menaquinone supplementation,
particularly the MK-7 subtype, in postmenopausal women with and without osteoporosis.
Clinical Impact on Cancer
In vitro studies have demonstrated that menaquinone possesses anti-cancer properties by
inducing cell cycle arrest and apoptosis in a number of cell types including leukemia, liver,
gastric, colorectal, lung, and prostate cancer.36-44 Level 2 observational studies indicate that
menaquinone intake may reduce the incidence and mortality of cancer (Table 3).45, 46 Nimptsch
et al. followed a cohort of 24,340 European adults over a period of ten to fourteen years;
participants were asked to fill out food frequency questionnaires to assess their menaquinone
intake.46 The study revealed an inverse relationship between menaquinone intake and overall
cancer incidence (HR = 0.86, 95% CI: 0.73-1.01), although this trend was non-significant (p =
0.08). There was a significant inverse relationship between menaquinone intake and overall
cancer mortality (HR = 0.72, 95% CI: 0.53-0.98, p = 0.03). When broken down by cancer type,
menaquinone intake was associated with a significantly lower incidence and mortality of lung
cancer. Menaquinone intake was also associated with a significantly lower incidence of prostate
cancer and overall incidence of cancer in men.46
The use of menaquinone in the treatment of hepatocellular carcinoma (HCC) has been
investigated by a number of level 2 RCTs.47-55 Two small trials examined the ability of
menaquinone (MK-4, 45 mg/day) to suppress the development of HCC in patients with hepatitis
C.54, 55 Both studies observed a lower proportion of patients develop HCC with menaquinone
treatment; however, this effect was statistically significant in only one study.54, 55 Several RCTs
have evaluated the effect of menaquinone (MK-4, 45 mg/day) in reducing recurrence and
mortality after surgical or ablative treatment of HCC.47-52 These studies have reported conflicting
results; some found a significant decrease in recurrence and mortality while others found no
effect.47-52 The majority of these studies were limited by small sample sizes (<100 patients) and
relatively short follow-up time (1-3 years).
The largest RCT involved 548 former HCC patients who were randomized to receive placebo, 45
mg/day MK-4, or 90 mg/day MK-4; menaquinone treatment was not found to reduce disease
occurrence or death (HR = 1.150, 95% CI: 0.843-1.570, p = 0.811), and the study was

discontinued after three years (Table 3).47 A level 2 meta-analysis of 5 RCTs observed
significantly reduced HCC recurrence at two and three years, but not one year; there was no
benefit to survival.56 Another level 2 meta-analysis of 6 RCTs and one cohort study also found
no significant reduction in recurrence at one year, but a significant reduction at two and three
years; this study found a significant improvement in overall survival.57 However, due to the
small sample sizes and relatively short follow-up times of the available clinical trials, more
research is needed to definitively understand the benefit of menaquinone in the prevention and
treatment of HCC.
Menaquinone Drug Interactions
Perhaps the most well-known drug interaction associated with vitamin K is the coumarin
derivative anticoagulants, namely warfarin. Although this interaction is classically described
with phylloquinone, recent evidence indicates that menaquinone can have a similar, if not more
potent reversal of coumarin-induced anticoagulation. Studies by Theuwissen et al. and Schurgers
et al. examined the effects MK-7 on the stability of oral anticoagulation with vitamin K
antagonists (coumarin derivatives) and found that MK-7 not only reverses anticoagulation, but is
even more effective than phylloquinone in reversing undercarboxylation of both hepatic (blood
coagulation factors) and extra-hepatic proteins (OC and MGP).58, 59 Thus, clinicians should be
aware that even low dose menaquinone supplementation (50 µg/day) could impact coumarininduced anticoagulation.58
Recently, menaquinone has been demonstrated to be a ligand for the pregnane X receptor
(PXR).60 PXR is a nuclear receptor with both a ligand and DNA binding domain. Once bound,
menaquinone forms a heterodimer with PXR, and this complex acts as a transcriptional regulator
for certain CYP 450 isozymes. One of the major targets of the PXR-K2 complex is the gene for
CYP3A4.60 This enzyme is responsible for metabolizing a wide variety of commonly used
medications, and induction can lower plasma concentrations of CYP3A4 substrates.61 Important
CYP3A4 substrates include members of the HMG-CoA reductase family, certain anti-epileptic
drugs and a wide variety of antimicrobials and antineoplastics.62 Although more research is
required to further elucidate the exact effect of menaquinone on the CYP3A4 enzyme, the results
of these studies at least support that caution should be exercised when menaquinone is taken
concurrently with known substrates.
Additionally, drugs such as bile-acid-sequestrants (cholestyramine, colestipol, colesevelam),
orlistat, and mineral oil, that interfere with the absorption of fat soluble vitamins, may interfere
with menaquinone supplementation by decreasing absorption of the vitamins.63-65 Patients taking
these medications should be instructed to take menaquinone at least an hour before or several
hours after their other medications.
Conclusion
Menaquinone supplementation has been shown to consistently improve carboxylation of OC and
MGP to their active forms; however, the clinical benefit of this effect has not been uniformly
demonstrated. In the setting of cardiovascular disease, menaquinone intake has been shown to
lower the risk of coronary calcification and coronary heart disease, and an RCT has

demonstrated that it can reduce arterial stiffness. In osteoporosis, menaquinone has been shown
by numerous RCTs to decrease the rate of bone loss at the lumbar spine and forearm and reduce
the risk of fracture. In cancer, menaquinone intake has been shown to reduce overall incidence
and mortality; RCTs have suggested that it may have a role in reducing recurrence and death
from hepatocellular carcinoma. However, in all clinical settings, more large RCTs with
ethnically diverse patient populations are needed to definitively determine the clinical benefits of
menaquinone supplementation, as many studies have failed to show any significant clinical
benefit. Lastly, more research is needed to determine how menaquinone supplementation
interacts with medications such as warfarin, bile-acid sequestrants, orlistat, mineral oil and
CYP3A4 substrates.
Figures and Tables

Figure 1. Mechanism of action for menaquinone in calcium regulation.

Table 1. Summary of studies evaluating the effect of menaquinone supplementation on
cardiovascular disease. Therapeutic levels of evidence are listed as described by Wright et al.66

Study

Level of
Evidence

Patient
Population

Beulens
et al.
200924

Level II Cross
sectional
study

564 Post
menopausal
Dutch
women

Geleijnse
et al.
2004 25

Level II –
Cohort
study

4807 men
and women
over age 55

Gast et al.
200926

Knapen et
al.28

Level II –
Cohort
study

Level II –
RCT

16,057 postmenopausal
Dutch
women

244 postmenopausal
Dutch
women

Supplementation
Dietary
menaquinone
intake estimated
by food
frequency
questionnaire,
average 31.6 ±
12.3 µg/day
Dietary
menaquinone
intake estimated
by food
frequency
questionnaire,
average 30.8 ±
18.0 µg/day
(men) and 27.0 ±
15.1 µg/day
(women)
Dietary
menaquinone
intake estimated
by food
frequency
questionnaire,
average 29.1 ±
12.8 µg/day

MK-7, 180
µg/day

Main
Outcome
Measurement

Coronary
calcification

Coronary
heart disease

Results
Menaquinone
intake associated
with decreased
coronary
calcification (RR
= 0.80, 95% CI:
0.65-0.98, p =
0.03)
Relative risk for
CHD mortality
was lower in the
mid and upper
tertiles of
menaquinone
intake (mid: RR =
0.73, 95% CI:
0.45-1.17; upper:
RR = 0.43, 95%
CI: 0.24-0.77)

Coronary
heart disease

Menaquinone
intake was
associated with a
decreased risk of
CHD (HR = 0.91,
95% CI: 0.851.00)

Carotid and
aortic
stiffness, duMGP

Menaquinone
supplementation
demonstrated a
significant
decrease in
arterial wall
stiffness after
three years and a
50% decrease in
du-MGP

Table 2. Summary of studies evaluating the effect of menaquinone supplementation on
osteoporosis.

Study

Level of
Evidence

Patient
Population

Supplementation

Main
Outcome
Measurement

Emaus et
al. 201016

Level I –
RCT

334 healthy
postmenopa
usal women

MK-7, 360
µg/day

BMD, cOC,
and uOC

Knapen
et al.
201329

Level I –
RCT

244 healthy
postmenopa
usal Dutch
women

MK-7, 180
µg/day

BMD, cOC,
uOC

Huang et
al. 201535

Level II –
Metaanalysis

19 RCTs
with 6759
participants

MK-4, 45 µg/day
(13 studies); MK7, 100-360
µg/day (4 studies)

BMD, cOC,
uOC, fractures

Results
No significant
difference in
BMD between
treatment and
control group at
12 months (p =
0.48). Treatment
group had
significantly
higher cOC and
lower uOC (p
<0.001).
Daily
menaquinone
supplementation
significantly
decreased bone
loss at lumbar
spine and
femoral neck
after 3 years (p =
0.014).
Treatment group
had significantly
higher cOC and
lower uOC (p <
0.001).
Significant
decrease in
vertebral bone
loss in women
with osteoporosis
(p = 0.0005).
Significant
overall increase
in cOC and
decrease in uOC
(p = 0.001).
Significant
reduction in

fracture
incidence (RR =
0.50, 95% CI:
0.33-0.74)

Table 3. Summary of studies evaluating the effect of menaquinone supplementation on cancer.

Study

Level of
Evidence

Patient
Population

Supplementation

Main
Outcome
Measurement

Nimptsch
et al.
2008

Level II –
Cohort
study

24,340
European
adults

Dietary
menaquinone
intake estimated
by food frequency
questionnaire

Yoshida
et al.
2011

Level I –
RCT

548 former
HCC
patients

MK-4, 45 or 90
µg/day

Disease
recurrence,
mortality

Riaz et al.
2012

Level II –
Metaanalysis

Five RCTs
with 754
former HCC
patients

MK-4, 45-90
µg/day

Disease
recurrence,
survival

Level II –
Metaanalysis

6 RCTs and
1 cohort
study with
930 former
HCC
patients

MK-4, 45-90
µg/day

Disease
recurrence,
survival

Zhong et
al. 2013

Cancer
incidence and
mortality

Results
Significant
inverse
relationship
between
menaquinone
intake and cancer
mortality (HR =
0.72, 95% CI:
0.53-0.98, p =
0.03)
Menaquinone
treatment was
not found to
decrease
recurrence or
morality, study
discontinued
after three years
Reduced HCC
recurrence at two
and three years,
but not one; no
benefit to
survival
Reduced HCC
recurrence at two
and three years,
but not one;
improved
survival
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